Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
The Journal of Organic Chemistry|November 25, 2003
Vinylalumination for the synthesis of functionalized allyl alcohols, vinylepoxides, and alpha-alkylidene-beta-hydroxy-gamma-lactonesP Veeraraghavan Ramachandran, Michael T Rudd, Thomas E Burghardt, et al.Organic Letters|November 5, 2004
Regioselectivity control in a ruthenium-catalyzed cycloisomerization of diyne-olsBarry M Trost, Michael T Rudd, Moisés Gulías Costa, et al.Antimicrobial Agents and Chemotherapy|October 21, 2009
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A proteaseNigel J Liverton, Steven S Carroll, Jillian Dimuzio, et al.Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.Nature Communications|February 6, 2021
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activationChuan Hong, Noel J Byrne, Beata Zamlynny, et al.Nature|April 6, 2017
Structural basis for selectivity and diversity in angiotensin II receptorsHaitao Zhang, Gye Won Han, Alexander Batyuk, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.Antimicrobial Agents and Chemotherapy|May 23, 2012
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variantsVincenzo Summa, Steven W Ludmerer, John A McCauley, et al.Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsUnmesh Shah, Charles Jayne, Samuel Chackalamannil, et al.Pageof 3